title: Tacrolimus plus low-dose mycophenolate mofetil in renal transplant recipients: better 2-year graft and patient survival than with a higher mycophenolate mofetil dose.
abstract: OBJECTIVE
  Mycophenolate mofetil (MMF) has become more widely prescribed in recent years, but its adverse effects on the gastrointestinal system and bone marrow restrict its use in certain settings. The aim of this study was to compare the demographic features and clinical data for 173 renal transplant recipients who received tacrolimus (TAC) plus 1 g/d MMF (group I, n = 112) versus TAC plus 2 g/d MMF (group II, n = 61 patients) over a 2-year period. Each patient received similar TAC doses.
  
  
  METHODS
  We compared demographic data and clinical data for each case: acute rejection (AR) episodes, chronic rejection (CR) episodes, death, graft loss, development of posttransplantation diabetes mellitus (PTDM), and posttransplantation hypertension rates.
  
  
  RESULTS
  Demographic features were similar. There were also no significant differences between groups I and II with respect to number of AR episodes (17/112 vs 12/61, respectively), number of CR episodes (4/112 vs 1/61, respectively), PTDM, and hypertension rate (P > .05). Kaplan-Meier survival analysis revealed 2-year graft survival rates of 94% in group I versus 83% in group II. The corresponding 2-year patient survival rates were 100% in group I versus 91% in group II. The graft survival and patient survival rates in group I were significantly higher than those in group II (log-rank 0.005 and 0.001, respectively).
  
  
  CONCLUSIONS
  The 2-year graft and patient survival rates for the renal transplant recipients in this study suggest that the combination of a full TAC dose with 1 g/d MMF is a better choice than 2 g/d MMF.
authors.affiliation: Department of Nephrology, Akdeniz University School of Medicine, Antalya, Turkey. hkocak@akdeniz.edu.tr
authors.forename: H
authors.initials: H
authors.lastname: Kocak
authors.forename: U
authors.initials: U
authors.lastname: Yakupoglu
authors.forename: G Uslu
authors.initials: GU
authors.lastname: Karatas
authors.forename: A
authors.initials: A
authors.lastname: Yavuz
authors.forename: A
authors.initials: A
authors.lastname: Gurkan
authors.forename: O
authors.initials: O
authors.lastname: Erdogan
authors.forename: F F
authors.initials: FF
authors.lastname: Ersoy
authors.forename: G
authors.initials: G
authors.lastname: Yakupoglu
authors.forename: A
authors.initials: A
authors.lastname: Demirbas
authors.forename: M
authors.initials: M
authors.lastname: Tuncer
mesh_terms: D000328:Adult; D003404:Creatinine / Q000097:blood; D004305:Dose-Response Relationship, Drug; D004359:Drug Therapy, Combination; D005260:Female; D006084:Graft Rejection / Q000453:epidemiology; D006085:Graft Survival / Q000187:drug effects / Q000276:immunology*; D006801:Humans; D016030:Kidney Transplantation / Q000276:immunology* / Q000401:mortality; D008297:Male; D008875:Middle Aged; D009173:Mycophenolic Acid / Q000031:analogs & derivatives* / Q000627:therapeutic use; D016019:Survival Analysis; D016559:Tacrolimus / Q000627:therapeutic use*
chemical_list: D003404:Creatinine; D009173:Mycophenolic Acid; D016559:Tacrolimus